Bionet

Bionet R&D per Employee

The R&D Spending per Employee of Bionet (1784.TWO) as of Nov 2, 2026 is 1.28 M TWD. In the previous year, R&D Spending per Employee was 1.18 M TWD — a change of 8.46% (higher).

R&D per Employee

1.28 MTWD

YoY

8.46%

Last updated:

R&D Spending per Employee of Bionet is 2025 1.28 M TWD. R&D Spending per Employee of Bionet was 2024 1.18 M TWD. It decreases by 8.46% higher compared to the previous year.

The Bionet R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
364,432.20 TWD
Jan 1, 2019
396,525.42 TWD
Jan 1, 2020
444,474.58 TWD
Jan 1, 2021
725,161.02 TWD
Jan 1, 2022
765,245.76 TWD
Jan 1, 2023
1.01 M TWD
Jan 1, 2024
1.18 M TWD
Jan 1, 2025
1.28 M TWD
The Bionet R&D per Employee history
YEARR&D per EmployeeYoY
1.28 MTWD+8.46%
1.18 MTWD+17.07%
1.01 MTWD+31.51%
765,245.76TWD+5.53%
725,161.02TWD+63.15%
444,474.58TWD+12.09%
396,525.42TWD+8.81%
364,432.20TWD+11.12%
327,974.58TWD+2.86%
318,847.46TWD-23.95%
419,271.19TWD-3.69%
435,322.03TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bionet Stock analysis

What does Bionet do? Bionet Corp. generates revenue through cell therapy, regenerative medicine, and medical big data services. Its main products include umbilical cord blood stem cells, mesenchymal stem cells, and adult peripheral blood stem cells, which are sold to domestic healthcare providers. The company also offers precision medical applications, prenatal testing, and genetic testing services to domestic clients. The firm primarily serves the domestic market within Taipei City, Taipei, focusing on medical and healthcare segments. Bionet Corp. targets healthcare institutions and medical facilities in Taiwan as its primary customers. The company's product portfolio includes stem cell therapies and genetic testing services, which are distributed through its domestic operations. Revenue streams are derived from both the sale of biological products and the provision of specialized medical services within the local market. The business model relies on domestic sales of stem cell-based therapies and genetic testing services. Products such as umbilical cord blood stem cells and mesenchymal stem cells are key revenue drivers, alongside precision medical applications and prenatal testing. All operations are conducted within Taiwan, with no mention of international markets or external partnerships. Bionet is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bionet stock

R&D Spending per Employee of Bionet is 1.28 M TWD in 2025.

R&D Spending per Employee of Bionet changed from 1.18 M TWD to 1.28 M TWD, representing a 8.46% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Bionet since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Bionet historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Bionet

All Key Metrics — Bionet